Overview
AI-driven oncology drug development.
Details
Lantern’s RADR platform identifies patient subsets and biomarkers for in-licensed oncology assets.
AI-driven oncology drug development. Lantern's RADR platform identifies patient subsets and biomarkers for in-licensed oncology assets.
AI-driven oncology drug development.
Lantern’s RADR platform identifies patient subsets and biomarkers for in-licensed oncology assets.